Nautilus Biotechnology Appoints Sales VP to Lead Late-2026 Voyager Platform Launch
Nautilus Biotechnology appointed Amber Faust as Vice President of Sales to spearhead commercial launch of its Voyager Platform in late 2026, securing pre-orders and managing instrument installations. Faust brings two decades of proteomics sales leadership at Olink, SomaLogic and Waters, joining after the Voyager debut and Early Access Program launch.
1. Appointment Overview
Nautilus Biotechnology named Amber Faust as Vice President of Sales to drive commercialization of its Voyager Platform. Faust will oversee sales strategy, secure pre-orders, manage instrument installations at customer sites and expand market reach ahead of the planned late-2026 launch.
2. Commercial Launch Plans
This appointment follows the public debut of the Voyager Platform and the launch of the Iterative Mapping Early Access Program. Faust’s role includes coordinating the full commercial launch, guiding market adoption of the single-molecule proteome analysis instrument and supporting early customer onboarding.
3. Executive Background
Faust brings two decades of proteomics and life sciences commercial leadership from Olink Proteomics, SomaLogic and Waters Corporation. Her expertise in introducing emerging proteomics technologies to pharmaceutical, academic and clinical sectors aligns with Nautilus’ goal to scale single-molecule protein analysis worldwide.